NCT00900302 — OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer · CancerIndex

Clinical trial · Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Study of The Examination of Sentinel Lymph Nodes for OX-40 Expression in Patients With Cancer

NCT00900302CI-TRIAL-00020857completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is evaluating OX-40 protein expression in the sentinel lymph nodes of patients with cancer.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Cancer	Malignant Neoplasm	ALIAS	0.90

Interventions

Interventions (4)

Intervention	Type	Mapped drug	Match
biopsy	Procedure	—	UNRESOLVED
immunohistochemistry staining method	Other	—	UNRESOLVED
laboratory biomarker analysis	Other	—	UNRESOLVED
protein expression analysis	Genetic	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (2)

measure
OX-40 expression
timeFrame
During immunostaining
description
The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining
measure
Disease-free survival
timeFrame
During data analysis
description
Kaplan-Maier method will be used to estimate the disease-free survival, and a log-rank test will be used to compare the disease-free survival between high vs. low OX-40 groups

Eligibility

Eligibility (as posted)

Sex: All
Maximum age: 120 Years

Show eligibility criteria text

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed cancer, including, but not limited to, the following:

  * Melanoma
  * Breast cancer
  * Invasive squamous cell cancer
  * Other cancers for which patients underwent or will undergo the following:

    * Adequate archived paraffin-embedded tissue for making slides for immunostaining
    * Adequate freshly removed sentinel lymph node (and primary tumor, if available) tissue for laboratory assays
* Clinical data and date of last follow-up on tumor stage and status must be available
* Hormone receptor status not specified

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: Apr 1, 2005
Primary completion: Mar 1, 2011
Completion: Mar 1, 2011
First posted: May 12, 2009
Last update posted: Feb 10, 2016
Enrollment: 98 (actual)
Lead sponsor: OHSU Knight Cancer Institute OTHER
Collaborators: National Cancer Institute (NCI)
Keywords: male breast cancer, recurrent breast cancer, stage IA breast cancer, stage IB breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, stage IV breast cancer, unspecified adult solid tumor, protocol specific, unspecified childhood solid tumor, protocol specific, squamous cell carcinoma of the anus, squamous cell carcinoma of the bladder, squamous cell carcinoma of the esophagus, squamous cell carcinoma of the gallbladder, squamous cell carcinoma of the skin, squamous cell carcinoma of the vulva, squamous cell lung cancer, vaginal squamous cell carcinoma, stage I squamous cell carcinoma of the hypopharynx, stage II squamous cell carcinoma of the hypopharynx, stage III squamous cell carcinoma of the hypopharynx, stage IV squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the hypopharynx, stage I squamous cell carcinoma of the larynx, stage I verrucous carcinoma of the larynx, stage II squamous cell carcinoma of the larynx, stage II verrucous carcinoma of the larynx, stage III squamous cell carcinoma of the larynx, stage III verrucous carcinoma of the larynx, stage IV squamous cell carcinoma of the larynx, stage IV verrucous carcinoma of the larynx, recurrent squamous cell carcinoma of the larynx, recurrent verrucous carcinoma of the larynx, stage I squamous cell carcinoma of the lip and oral cavity, stage II squamous cell carcinoma of the lip and oral cavity, stage III squamous cell carcinoma of the lip and oral cavity, stage IV squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the lip and oral cavity, stage I verrucous carcinoma of the oral cavity, stage II verrucous carcinoma of the oral cavity, stage III verrucous carcinoma of the oral cavity, stage IV verrucous carcinoma of the oral cavity, recurrent verrucous carcinoma of the oral cavity, metastatic squamous neck cancer with occult primary squamous cell carcinoma, recurrent metastatic squamous neck cancer with occult primary, untreated metastatic squamous neck cancer with occult primary, stage I squamous cell carcinoma of the nasopharynx, stage II squamous cell carcinoma of the nasopharynx, stage III squamous cell carcinoma of the nasopharynx, stage IV squamous cell carcinoma of the nasopharynx, recurrent squamous cell carcinoma of the nasopharynx, stage I squamous cell carcinoma of the oropharynx, stage II squamous cell carcinoma of the oropharynx, stage III squamous cell carcinoma of the oropharynx, stage IV squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the oropharynx, stage I squamous cell carcinoma of the paranasal sinus and nasal cavity, stage II squamous cell carcinoma of the paranasal sinus and nasal cavity, stage III squamous cell carcinoma of the paranasal sinus and nasal cavity, stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity, recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity, salivary gland squamous cell carcinoma, stage I salivary gland cancer, stage II salivary gland cancer, stage III salivary gland cancer, stage IV salivary gland cancer, recurrent salivary gland cancer, squamous cell carcinoma of unknown primary, cervical squamous cell carcinoma, penile squamous cell carcinoma, recurrent anal cancer, stage I anal cancer, stage II anal cancer, stage IIIA anal cancer, stage IIIB anal cancer, stage IV anal cancer, recurrent bladder cancer, stage I bladder cancer, stage II bladder cancer, stage III bladder cancer, stage IV bladder cancer, recurrent esophageal cancer, stage I esophageal cancer, stage II esophageal cancer, stage III esophageal cancer, stage IV esophageal cancer, localized gallbladder cancer, recurrent gallbladder cancer, unresectable gallbladder cancer, recurrent vulvar cancer, stage I vulvar cancer, stage II vulvar cancer, stage III vulvar cancer, stage IV vulvar cancer, recurrent cervical cancer, stage IA cervical cancer, stage IB cervical cancer, stage IIA cervical cancer, stage IIB cervical cancer, stage III cervical cancer, stage IVA cervical cancer, stage IVB cervical cancer, recurrent non-small cell lung cancer, stage I non-small cell lung cancer, stage II non-small cell lung cancer, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer, recurrent skin cancer, newly diagnosed carcinoma of unknown primary, recurrent carcinoma of unknown primary, recurrent penile cancer, stage I penile cancer, stage II penile cancer, stage III penile cancer, stage IV penile cancer, recurrent melanoma, stage IA melanoma, stage IB melanoma, stage IIA melanoma, stage IIB melanoma, stage IIC melanoma, stage IIIA melanoma, stage IIIB melanoma, stage IIIC melanoma, stage IV melanoma